EDTUTC-4 New YorkLog in Sign up

TEVA
Teva Pharmaceutical Industries Limited
stockNYSE

At CloseOct 21, 2026 3:59:58 PM EDT

40.61USD-0.588%(-0.24)4,594,108

Pre-marketOct 21, 2026 9:29:30 AM EDT

40.19USD-1.616%(-0.66)

After-hoursOct 21, 2026 4:32:30 PM EDT

40.58USD-0.074%(-0.03)

35.30Bid46.67Ask11.37Spread

TEVA News

Day breaks

08:26 AM EDTUEG Week: Teva and Sanofi’s Duvakitug Maintained Long-Term Positive Outcomes in New Phase 2b Data for Ulcerative Colitis and Crohn’s Disease ·

Financial Post

08:02 AM EDTAlvotech wins FDA nod for new manufacturing process for Humira biosimilar ·

Seeking Alpha

05:49 PM EDTTeva to Host R&D Day on Wednesday, November 11 in New York City ·

Financial Post

05:45 PM EDTTeva to Host R&D Day on Wednesday, November 11 in New York City ·

GlobeNewswire Inc.

10:57 AM EDTHospital group files lawsuit to stop 340B rebate pilot again ·

Seeking Alpha

12:53 PM EDTTeva Pharmaceutical Industries Limited (TEVA) Discusses FDA Approval of Weltruza and Strategic Growth Initiatives Transcript ·

Seeking Alpha

11:21 AM EDTTeva gains approval of monthly olanzapine injection for schizophrenia ·

Seeking Alpha

07:17 AM EDTFDA Approves Teva's Once-Monthly Injectable Olanzapine ·

RTTNews

07:00 AM EDTTeva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia ·

GlobeNewswire Inc.

02:37 PM EDTAbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot ·

Seeking Alpha

09:16 AM EDTTeva Reports New Efficacy, Safety Data For Ecopipam In Pediatric Tourette Syndrome ·

RTTNews

08:05 AM EDTTeva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome ·

Financial Post

08:05 AM EDTJournal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients ·

Financial Post

08:00 AM EDTTeva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome ·

GlobeNewswire Inc.

08:00 AM EDTJournal of Child Neurology Publishes Review Highlighting Dopamine’s Role in Tourette Syndrome and Ecopipam’s Selective D1 Receptor Mechanism for Tourette Syndrome in Pediatric Patients ·

GlobeNewswire Inc.

04:54 AM EDTTeva and Samsung Bioepis partner on up to six biosimilars ·

Seeking Alpha

04:32 AM EDTSamsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates ·

Financial Post

05:26 PM EDTTeva names Serge Rogasik as CEO of API, CDMO business ·

Seeking Alpha

04:32 PM EDTTAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness ·

GlobeNewswire Inc.

05:55 AM EDTTeva Pharmaceutical: 3 Numbers That Explain This Generic-Drug Turnaround ·

The Motley Fool